Tezacaftor and Ivacaftor

Brand names: Symdeko
Drug class: Antineoplastic Agents

Usage of Tezacaftor and Ivacaftor

Cystic Fibrosis

Treatment of cystic fibrosis in patients ≥6 years of age who are homozygous for F508del mutation in the CFTR gene or have at least 1 mutation in the CFTR gene that is responsive to the combination drug regimen.

Designated an orphan drug by FDA for treatment of cystic fibrosis.

If the genotype of the patient is not known, use an FDA-approved cystic fibrosis mutation test to detect presence of CFTR mutations followed by verification with bidirectional sequencing when recommended by the mutation test instructions.

The 2018 Cystic Fibrosis Foundation pulmonary guideline specifically addresses the use of CFTR modulators in patients with cystic fibrosis. Tezacaftor/ivacaftor was approved after publication of the guideline, and therefore is not addressed.

Relate drugs

How to use Tezacaftor and Ivacaftor

General

Pretreatment Screening

  • Select patients for treatment with tezacaftor/ivacaftor based on whether they have 2 copies of the F508del mutation or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay data. If the patient's genotype is unknown, use an FDA-approved cystic fibrosis mutation test to detect presence of a CFTR mutation followed by verification with bidirectional sequencing when recommended by the mutation test instructions.
  • Obtain baseline serum ALT and AST concentrations.
  • Baseline ophthalmologic examinations recommended in pediatric patients.

    • Patient Monitoring

  • Assess serum ALT and AST concentrations every 3 months during the first year of therapy and annually thereafter. In patients with a history of ALT or AST elevations, consider more frequent monitoring. Closely monitor patients who develop increased ALT, AST, or bilirubin concentrations until abnormalities resolve.
  • Follow-up ophthalmologic examinations recommended in pediatric patients.

    • Administration

    Oral Administration

    Administer orally with fat-containing food (e.g., eggs, cheese, nuts, whole milk, meats, food prepared with butter or oils) to increase systemic absorption of the drug.

    Swallow tablets whole.

    Dosage

    Available as a kit containing 4 weekly blister cards of 7 tablets containing 100 mg of tezacaftor in fixed combination with 150 mg of ivacaftor copackaged with 7 tablets containing 150 mg of single-entity ivacaftor.

    Also available as a kit containing 4 weekly blister cards of 7 tablets containing 50 mg of tezacaftor in fixed combination with 75 mg of ivacaftor copackaged with 7 tablets containing 75 mg of single-entity ivacaftor.

    Pediatric Patients

    Cystic Fibrosis Oral

    Children 6 to <12 years of age weighing <30 kg: Tezacaftor 50 mg/ivacaftor 75 mg once daily in the morning and single-entity ivacaftor 75 mg once daily in the evening (taken approximately 12 hours apart).

    Children 6 to <12 years of age weighing ≥30 kg: Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning and single-entity ivacaftor 150 mg once daily in the evening (taken approximately 12 hours apart).

    Children ≥12 years of age: Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning and single-entity ivacaftor 150 mg once daily in the evening (taken approximately 12 hours apart).

    Dosage adjustment necessary when used concomitantly with moderate or strong inhibitors of CYP3A.

    Dosage Modification for Concomitant Use of Moderate or Strong CYP3A Inhibitors Oral

    Pediatric patients 6 to <12 years of age weighing <30 kg receiving a moderate CYP3A inhibitor (e.g., erythromycin, fluconazole): administer tezacaftor 50 mg/ivacaftor 75 mg fixed-combination tablets once every other day and single-entity ivacaftor 75 mg once every other day, on alternate days in the morning. Do not administer the evening dose of single-entity ivacaftor 75 mg in such patients.

    Pediatric patients 6 to <12 years of age weighing ≥30 kg receiving a moderate CYP3A inhibitor (e.g., erythromycin, fluconazole): administer 100 mg/ivacaftor 150 mg fixed-combination tablets once every other day and single-entity ivacaftor 150 mg once every other day, on alternate days in the morning. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Pediatric patients ≥12 years of age receiving a moderate CYP3A inhibitor (e.g., erythromycin, fluconazole): administer tezacaftor 100 mg/ivacaftor 150 mg fixed-combination tablets once every other day and single-entity ivacaftor 150 mg once every other day, on alternate days in the morning. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Pediatric patients 6 to <12 years of age weighing <30 kg receiving a strong CYP3A inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole): administer tezacaftor 50 mg/ivacaftor 75 mg fixed-combination tablets twice weekly, approximately 3–4 days apart. Do not administer the evening dose of single-entity ivacaftor 75 mg in such patients.

    Pediatric patients 6 to <12 years of age weighing ≥30 kg receiving a strong CYP3A inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole): administer tezacaftor 100 mg/ivacaftor 150 mg fixed-combination tablets twice weekly, approximately 3–4 days apart. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Pediatric patients ≥12 years of age receiving a strong CYP3A inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole): administer tezacaftor 100 mg/ivacaftor 150 mg fixed-combination tablets twice weekly, approximately 3–4 days apart. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Adults

    Cystic Fibrosis Oral

    Tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning and single-entity ivacaftor 150 mg once daily in the evening (taken approximately 12 hours apart).

    Dosage adjustment necessary when used concomitantly with moderate or strong inhibitors of CYP3A.

    Dosage Modification for Concomitant Use of Moderate or Strong CYP3A Inhibitors Oral

    Concomitant use of a moderate CYP3A inhibitor (e.g., erythromycin, fluconazole): administer tezacaftor 100 mg/ivacaftor 150 mg fixed-combination tablets once every other day and single-entity ivacaftor 150 mg once every other day, given on alternate days in the morning. Do not administer the evening dose of single-entity ivacaftor 150 mg.

    Concomitant use of a strong CYP3A inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole): administer tezacaftor 100 mg/ivacaftor 150 mg fixed-combination tablets twice weekly, approximately 3–4 days apart. Do not administer the evening dose of single-entity ivacaftor 150 mg.

    Special Populations

    Hepatic Impairment

    Mild hepatic impairment (Child-Pugh class A): Dosage adjustment not necessary.

    Patients 6 to <12 years of age weighing <30 kg with moderate hepatic impairment (Child-Pugh class B): tezacaftor 50 mg/ivacaftor 75 mg once daily in the morning. Do not administer the evening dose of single-entity ivacaftor 75 mg in such patients.

    Patients 6 to <12 years of age weighing ≥30 kg with moderate hepatic impairment (Child-Pugh class B): tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Patients ≥12 years of age with moderate hepatic impairment (Child-Pugh class B): tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Patients 6 to <12 years of age weighing <30 kg with severe hepatic impairment (Child-Pugh class C): tezacaftor 50 mg/ivacaftor 75 mg once daily in the morning or less frequently. Do not administer the evening dose of single-entity ivacaftor 75 mg in such patients.

    Patients 6 to <12 years of age weighing ≥30 kg with severe hepatic impairment (Child-Pugh class C): tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning or less frequently. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Patients ≥12 years of age with severe hepatic impairment (Child-Pugh class C): tezacaftor 100 mg/ivacaftor 150 mg once daily in the morning or less frequently. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients.

    Renal Impairment

    Mild to moderate renal impairment: Dosage adjustment not necessary.

    Severe renal impairment or end-stage renal disease (ESRD): Caution advised.

    Geriatric Patients

    No specific dosage recommendations at this time.

    Warnings

    Contraindications

  • None.

    • Warnings/Precautions

    Hepatic Effects

    Elevated ALT or AST concentrations reported.

    Assess serum ALT and AST concentrations prior to initiation of therapy, every 3 months during the first year, and annually thereafter. In patients with a history of ALT or AST elevations, consider more frequent monitoring. Closely monitor patients who develop increased ALT, AST, or bilirubin concentrations until abnormalities resolve.

    Interrupt therapy in patients with ALT or AST elevations >5 times the ULN or in those with ALT or AST elevations >3 times the ULN when associated with elevated bilirubin concentrations >2 times the ULN. Following resolution of ALT or AST elevations, consider benefits and risks of resuming therapy.

    Interactions with CYP3A Inducers

    Concomitant use with strong CYP3A inducers substantially decreases systemic exposure of ivacaftor and may decrease exposure of tezacaftor; decreased exposures may reduce therapeutic efficacy. Concomitant use with strong CYP3A inducers not recommended. (See Interactions.)

    Ocular Effects

    Ocular lens opacities (not congenital in nature) reported in pediatric patients receiving tezacaftor/ivacaftor combination therapy or ivacaftor monotherapy. Baseline and follow-up ophthalmologic examinations recommended in pediatric patients.

    Specific Populations

    Pregnancy

    Limited data available regarding use of tezacaftor/ivacaftor combination therapy or its individual components in pregnant women. Evidence of teratogenicity or adverse effects on fetal development not observed in animals receiving tezacaftor or ivacaftor. No animal data available with concomitant use of tezacaftor and ivacaftor. Placental transfer of tezacaftor observed in pregnant rats; placental transfer of ivacaftor observed in pregnant rats and rabbits.

    Lactation

    Distributed into milk in rats; not known whether distributed into human milk. Consider developmental and health benefits of breast-feeding and clinical importance of therapy to the woman when deciding whether to use caution or discontinue nursing. Effects of tezacaftor/ivacaftor in fixed combination on nursing infants or milk production unknown.

    Pediatric Use

    Safety and efficacy not established in pediatric patients <6 years of age.

    Efficacy in patients 6 to <12 years of age extrapolated from efficacy results in patients ≥12 years of age with support from population pharmacokinetic analyses demonstrating similar drug exposures in patients 6 to <12 years of age and those ≥12 years of age. Safety profile in patients 6 to <12 years of age similar to that observed in patients ≥12 years of age.

    Geriatric Use

    Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.

    Hepatic Impairment

    Mild hepatic impairment (Child-Pugh class A): Effect on pharmacokinetics not studied; dosage adjustment not necessary.

    Moderate hepatic impairment (Child-Pugh class B): Increased exposure; dosage reduction recommended.

    Severe hepatic impairment (Child-Pugh class C): Effect on pharmacokinetics not studied, but increased exposure expected. Use with caution and at reduced dosage after weighing risks and benefits of therapy.

    Renal Impairment

    Not studied in patients with moderate or severe renal impairment or in those with ESRD.

    Mild or moderate renal impairment: Dosage adjustment not necessary.

    Severe renal impairment (Clcr ≤30 mL/minute) or ESRD: Use with caution.

    Common Adverse Effects

    Adverse effects (≥3% of patients): headache, nausea, sinus congestion, dizziness.

    What other drugs will affect Tezacaftor and Ivacaftor

    Tezacaftor is a substrate of CYP3A isoenzymes (e.g., CYP3A4, CYP3A5), P-glycoprotein (P-gp) transport, breast cancer resistance protein (BCRP), and organic anion transporting polypeptide (OATP) 1B1.

    Ivacaftor is a sensitive substrate of CYP3A. In vitro, ivacaftor has potential to inhibit CYP3A and P-gp, and also may inhibit CYP2C9.

    Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

    CYP3A substrates: No dosage adjustment needed.

    Strong CYP3A inhibitors: Pharmacokinetic interaction (possible increased tezacaftor and ivacaftor exposures). Reduce dosage to tezacaftor 100 mg/ivacaftor 150 mg in fixed combination twice weekly, approximately 3–4 days apart. Do not administer single-entity ivacaftor 150 mg.

    Moderate CYP3A inhibitors: Pharmacokinetic interaction (possible increased tezacaftor and ivacaftor exposures). In adults, children ≥12 years of age, and children 6 to <12 years of age weighing ≥30 kg, reduce dosage to tezacaftor 100 mg/ivacaftor 150 mg in fixed combination once every other day in combination with single-entity ivacaftor 150 mg once every other day, given on alternate days. Do not administer the evening dose of single-entity ivacaftor 150 mg in such patients. In children 6 to <12 years of age weighing <30 kg, reduce dosage to tezacaftor 50 mg/ivacaftor 75 mg in fixed combination once every other day in combination with single-entity ivacaftor 75 mg once every other day, given on alternate days. Do not administer the evening dose of single-entity ivacaftor 75 mg in such patients.

    Strong CYP3A inducers: Pharmacokinetic interaction (decreased ivacaftor exposure; decreased tezacaftor exposure expected). Concomitant use not recommended.

    Drugs Affected by P-glycoprotein Transport

    P-gp substrates: Pharmacokinetic interaction (possible increased exposure, prolonged therapeutic effect, or increased risk of adverse effects of the substrate drug). Use P-gp substrates with narrow therapeutic index concomitantly with caution; monitor patients appropriately.

    Specific Drugs

    Drug or Food

    Interaction

    Comments

    Anticonvulsants (Carbamazepine, phenobarbital, phenytoin)

    Possible decreased tezacaftor and ivacaftor exposures and reduced efficacy of tezacaftor/ivacaftor

    Concomitant use not recommended

    Antifungals, azoles (fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole)

    Itraconazole: Concomitant use with tezacaftor/ivacaftor results in 4- and 15.6-fold increased tezacaftor and ivacaftor AUCs, respectively

    Fluconazole: Concomitant use with ivacaftor results in threefold increased ivacaftor AUC; concomitant use with tezacaftor may increase tezacaftor exposures approximately twofold

    Itraconazole, ketoconazole, posaconazole, voriconazole: In adults, children ≥12 years of age, and children 6 to <12 years of age weighing ≥30 kg, reduce dosage to tezacaftor 100 mg/ivacaftor 150 mg twice weekly, approximately 3–4 days apart (do not administer the evening dose of single-entity ivacaftor 150 mg); in children 6 to <12 years of age weighing <30 kg, reduce dosage to tezacaftor 50 mg/ivacaftor 75 mg twice weekly, approximately 3–4 days apart (do not administer the evening dose of single-entity ivacaftor 75 mg)

    Fluconazole: In adults, children ≥12 years of age, and children 6 to <12 years of age weighing ≥30 kg, reduce dosage to tezacaftor 100 mg/ivacaftor 150 mg once every other day and single-entity ivacaftor 150 mg once every other day, given on alternate days (do not administer the evening dose of single-entity ivacaftor 150 mg); in children 6 to <12 years of age weighing <30 kg, reduce dosage to tezacaftor 50 mg/ivacaftor 75 mg in fixed combination once every other day in combination with single-entity ivacaftor 75 mg once every other day, given on alternate days (do not administer the evening dose of single-entity ivacaftor 75 mg)

    Antimycobacterials (rifabutin, rifampin)

    Rifabutin: Possible decreased tezacaftor and ivacaftor exposures and reduced efficacy of tezacaftor/ivacaftor

    Rifampin: Decreased ivacaftor exposure by 89%; decreased tezacaftor exposure also expected; possible reduced efficacy of tezacaftor/ivacaftor

    Concomitant use not recommended

    Ciprofloxacin

    No clinically important effect on tezacaftor or ivacaftor exposures

    Dosage adjustment not needed

    Digoxin

    Increased digoxin exposure; possible prolonged therapeutic effect of digoxin or increased risk of digoxin-associated adverse effects

    Use concomitantly with caution and appropriately monitor

    Erythromycin

    Possible increased tezacaftor and ivacaftor exposures

    In adults, children ≥12 years of age, and children 6 to <12 years of age weighing ≥30 kg, reduce dosage to tezacaftor 100 mg/ivacaftor 150 mg once every other day and single-entity ivacaftor 150 mg once every other day, given on alternate days (do not administer the evening dose of single-entity ivacaftor 150 mg); in children 6 to <12 years of age weighing <30 kg, reduce dosage to tezacaftor 50 mg/ivacaftor 75 mg in fixed combination once every other day in combination with single-entity ivacaftor 75 mg once every other day, given on alternate days (do not administer the evening dose of single-entity ivacaftor 75 mg)

    Estrogens and progestins

    Ethinyl estradiol and norethindrone: No substantial effect on exposures of ethinyl estradiol, norethindrone, tezacaftor, or ivacaftor

    Hormonal contraceptives: Concomitant use not expected to affect efficacy of hormonal contraceptives

    Grapefruit or grapefruit juice

    Possible increased tezacaftor and ivacaftor exposures

    Avoid concomitant use

    Immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus)

    Possible increased immunosuppressant exposures, prolonged therapeutic effect, or increased risk of immunosuppressant-associated adverse effects

    Use concomitantly with caution; monitor patients appropriately

    Pitavastatin

    No substantial effect on pitavastatin exposure

    St. John’s wort (Hypericum perforatum)

    Possible decreased tezacaftor and ivacaftor exposures and reduced efficacy of tezacaftor/ivacaftor

    Concomitant use not recommended

    Sulfonylureas

    Glimepiride, glipizide: Possible increased exposure of glimepiride or glipizide (CYP2C9 substrates)

    Use concomitantly with caution

    Warfarin

    Possible increased exposure of warfarin (CYP2C9 substrate)

    Monitor INR

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant